|
GB0217920D0
|
|
Interleukin-4 Gene Expression inhibitors
|
|
US2002146829A1
|
|
Neutral and anionic colloidal particles for gene delivery
|
|
ZA200109709B
|
|
Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT.
|
|
GB0127615D0
|
|
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
MXPA03003774A
|
|
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents.
|
|
GB0125885D0
|
|
Chiral preparation of a diastereomeric compound
|
|
GB0124976D0
|
|
A novel G protein-coupled receptor gave8
|
|
GB0124895D0
|
|
A mouse unable to express functional alpha-4 integrin protein and methods for assaying agents for alpha-4 integrin protein antagonist activity
|
|
IL155189D0
|
|
NOVEL CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
|
|
GB0123571D0
|
|
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
|
|
GB0119438D0
|
|
Gap junction permeability assay
|
|
GB0120124D0
|
|
Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
|
|
GB0119435D0
|
|
Method of treating of demyelinating diseases or conditions
|
|
GB0117706D0
|
|
Automated semi-solid matrix assay and liquid handler apparatus for the same
|
|
GB0117577D0
|
|
Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
|
|
GB0117531D0
|
|
Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
|
|
GB0117075D0
|
|
Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
|
HRP20010464A2
|
|
Process for preparing n6-substituted deaza-adenosine derivatives
|
|
AU6105401A
|
|
Nucleic acids encoding a novel regulator of g protein signaling, rgs18, and usesthereof
|
|
GB0108903D0
|
|
Novel crystalline forms of a factor Xa inhibitor
|
